Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12835484 | 1.00 | ALDH1A1 (0.32) | ALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL8071224 | 0.79 | SMN1; SMN2 (0.55) | ALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL8060386 | 0.79 | SMN1; SMN2 (0.55) | ALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL10308606 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL10308563 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL12835860 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL8060390 | 0.79 | SMN1; SMN2 (0.55) | ALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL26206636 | 0.77 | TSHR (0.36) | ALDH1A1TDP1 | |
| SCHEMBL10308352 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TDP1 | |
| SCHEMBL21670267 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110028552-A1 | MEXILETINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC | 2011-02-03 | — | — | US | disclosed |
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-11-11 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286186-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | VIP, OPRL1, OPRK1 | ALDH1A1 1313/4885TDP1 3591/4885SMN1; SMN2 2249/4885 |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | ALDH1A1 3187/4885TDP1 264/4885SMN1; SMN2 1522/4885 |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | ALDH1A1 327/4885TDP1 3075/4885SMN1; SMN2 2362/4885 |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | ALDH1A1 3187/4885TDP1 264/4885SMN1; SMN2 1522/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | ALDH1A1 677/4885TDP1 224/4885SMN1; SMN2 1474/4885 |
| US-20110028552-A1 | MEXILETINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | VIP, TRPV1, LNPEP | ALDH1A1 2722/4885TDP1 1342/4885SMN1; SMN2 952/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | ALDH1A1 677/4885TDP1 224/4885SMN1; SMN2 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.